Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine

NEW YORK, April 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

PerkinElmer, Inc. Analyst Notes 

On April 4, 2014, PerkinElmer, Inc. (PerkinElmer) announced that intends to release its Q1 2014 financial results on April 24, 2014, after market close. On the same day, the Company has scheduled a conference call at 5:00 p.m. ET to discuss the results. PerkinElmer informed that its Chairman and CEO, Robert F. Friel, and Senior Vice President and CFO, Andy Wilson, will host the conference call. The full analyst notes on PerkinElmer, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/PKI/report.pdf

--

PAREXEL International Corporation Analyst Notes 

On April 1, 2014, PAREXEL International Corporation (PAREXEL) announced that it intends to release its financial results for Q3 FY 2014 on April 29, 2014, after the close of the stock market. On the following day, April 30, 2014, the Company has scheduled a conference call and live webcast at 10:00 a.m. EDT to discuss the results. The full analyst notes on PAREXEL International Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04092014/PRXL/report.pdf

--

WuXi PharmaTech (Cayman) Inc. Analyst Notes 

On April 1, 2014, WuXi PharmaTech (Cayman) Inc. (WuXi) announced that WuXi Corporate Venture Fund has made an investment in TruTag Technologies, Inc. (TruTag). The Company informed that TruTag is a developer of the leading edible, covert security platform to address the global product counterfeiting challenge. In addition, the Companies announced that they will explore collaborations to offer WuXi's global customers the TruTag on-dose authentication solution to help prevent counterfeiting and to enhance drug safety. "WuXi is pleased to invest in this cutting-edge technology and to explore its further development to enhance patient safety and protect our customers' intellectual property," said Dr. Ge Li, Chairman and CEO of WuXi. The full analyst notes on WuXi PharmaTech (Cayman) Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/WX/report.pdf

--

Response Genetics, Inc. Analyst Notes 

On April 3, 2014, Response Genetics, Inc. (Response Genetics) announced that it has signed agreements with six additional health plans across 10 states, bringing the Company's total national contracted membership to more than 174 million customers. Response Genetics stated that these new agreements mark a further step forward in the Company's growing managed care contracting program. Also, the Company said that with these agreements, Response Genetics is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to Response Genetics to approximately 23 million. The full analyst notes on Response Genetics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/RGDX/report.pdf

--

Foundation Medicine, Inc. Analyst Notes 

On April 3, 2014, Foundation Medicine, Inc. (Foundation Medicine) announced the expansion of its ongoing collaboration with Clovis Oncology, Inc. (Clovis) to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval (PMA) companion diagnostic test, designed for use by physicians to identify patients most likely to respond to rucaparib. "In addition to helping bring an important new therapy to patients with ovarian cancer, this collaboration marks a paradigm shift in the development of companion diagnostics. The use of Foundation Medicine's platform is an important step in the evolution of cancer care from a static, single-gene companion diagnostic approach toward a universal companion diagnostic standard," said Michael J. Pellini, M.D., President and CEO of Foundation Medicine. "This agreement complements Foundation Medicine's plans to develop an FDA-approved companion diagnostic and supports our overall strategy to work with the FDA to establish the appropriate regulatory framework for novel, comprehensive genomic profiling platforms. We are very pleased to continue our support of Clovis' highly differentiated clinical development program and maintain our efforts with the company to identify the ovarian cancer patients most likely to benefit from rucaparib." The full analyst notes on Foundation Medicine, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/FMI/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED